Early FDA/Sponsor Meetings Expedite Novel Product Reviews In Some Cases
This article was originally published in The Gray Sheet
Executive Summary
Multiple review cycles for emerging technologies would be reduced, but not entirely eliminated, if industry and FDA were to meet earlier in the product development process, the agency finds
You may also be interested in...
Guidance Highlights Preclinical Testing Issues For Combination Products
A new guidance document from FDA discusses the types of scientific and technical data that may be needed to establish the safety and efficacy of novel combination products
Guidance Highlights Preclinical Testing Issues For Combination Products
A new guidance document from FDA discusses the types of scientific and technical data that may be needed to establish the safety and efficacy of novel combination products
Local Interest: FDA Surveys Targeted Drug-Delivery Device Landscape
Active delivery devices should demonstrate safety for both the device alone and its use with any intended biologics or drugs, according to FDA reps